Trials / Completed
CompletedNCT07218172
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 197 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A retrospective, observational, one arm, single country study, using the computerized database of Maccabi Health Services (MHS). The study will include adult patients who initiated benralizumab treatment for SEA between January 1, 2019, and March 31, 2024. The study population will include both biologic-naive and biologic-experienced patients. Patients will be followed from 12 months before the index date until the earliest of the following dates: switching, death, leaving MHS or end of the study follow-up period (June 30, 2024).
Conditions
Timeline
- Start date
- 2025-03-24
- Primary completion
- 2025-04-24
- Completion
- 2025-04-24
- First posted
- 2025-10-20
- Last updated
- 2025-10-20
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT07218172. Inclusion in this directory is not an endorsement.